Unibest

Pharmaceutical intermediates

Moxifloxacin hydrochloride Intermediates

2 pharmaceutical intermediates for Moxifloxacin hydrochloride. Indication: Bacterial conjunctivitis; Sinusitis; Pneumonia; Respiratory tract infection.

提交项目All intermediates

About Moxifloxacin hydrochloride

Originator
Bayer Healthcare Pharmaceuticals Inc
Indication
Bacterial conjunctivitis; Sinusitis; Pneumonia; Respiratory tract infection
Approved Date
12/10/1999

Available intermediates

2 intermediates currently listed for Moxifloxacin hydrochloride. Request specifications, documentation or a quotation for any item below.

Moxifloxacin hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid ethyl ester112811-71-9//
CIS-OCTAHYDROPYRROLO[3,4-B]PYRIDINE151213-40-0//

Other programs under M

MaribavirMaxacalcitolMetoclopramide HClMicafungin SodiumMilvexianMirogabalin besilateMolnupiravirMomelotinib Dihydrochloride Monohydrate

Building toward Moxifloxacin hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →